ROCHESTER, Minn. — A Mayo Clinic-led group of researchers has discovered three subgroups of a single type of non-Hodgkin lymphoma that have markedly different survival rates. These subgroups could not be differentiated by routine pathology but only with the aid of novel genetic tests, which the research team recommends giving to all patients with ALK-negative anaplastic large-cell lymphoma (ALCL). Findings are published in the journal Blood.
Recent Posts
- Leveraging the Full Potential of Regenerative Medicine Requires a Proactive Approach
- Implantable islet cells could control diabetes without insulin injections
- With FDA go ahead, a China biotech notches a first in cell therapy testing
- Japan Approves the World’s First Treatment Made With Reprogrammed Human Cells
- New RNA injection could help hearts heal after heart attacks
- Cells can sense 10x farther than expected and it may explain cancer spread
